EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effectiveness and safety of low dose Rituximab as remission-maintenance treatment for patients with refractory idiopathic inflammatory myopathies: results of a retrospective study from a monocentric cohort

Anna Gamba, Roberto Depascale, Elisabetta Zanatta, Luana Ienna, Claudio Cruciani, Mariele Gatto, Margherita Zen, Andrea Doria, Luca Iaccarino

Clinical Rheumatology · 2024

DOI: 10.1007/s10067-024-07079-z ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Rheumatology, 2024. Verfasst von Anna Gamba und 8 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology Unit, Division of Rheumatology, Department of Medicine-DIMED, University of Padova, Via Giustiniani, 2, 35128, Padova, Italy. Hauptthemen laut MEDLINE: Rituximab, Myositis, Remission Induction. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Padova.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Our aim was to assess efficacy and safety of Rituximab (RTX) in patients with refractory Idiopathic inflammatory myopathies (IIM) from a monocentric cohort. Thereafter, we evaluated the efficacy of a low-dose RTX regimen as a remission-maintenance therapy.

Methods

We retrospectively evaluated a cohort of patients affected with IIM treated with RTX. All patients were refractory to glucocorticoids (GC) and at least one immunosuppressant. Two infusions of 1 g two weeks apart were considered as standard cycle of RTX, a single dose of 1 g every six months was deemed as a low-dose RTX regimen. Complete and partial response were defined according to physician’s judgment, laboratory and radiological features.

Results

Thirty-six patients affected with IIM were enrolled. Eighteen patients (50%) required the use of RTX for muscular involvement, 6 (16.7%) for interstitial lung disease (ILD), 12 (33.3%) for both myositis and ILD. We observed complete response to RTX in 25 patients (69.4%), partial response in 7 (19.4%) and no response in 4 (11.1%), with an overall response of 88.8% (partial and complete response). From the subgroup of twenty-five patients that achieved a complete response, six were treated with a low dose maintenance therapy maintaining a complete response to RTX. Twenty-six patients who achieved a complete or partial response were able to decrease the mean daily GC dose. Infections were the major adverse events detected in our study.

Conclusions

RTX shows favorable outcomes in refractory patients with IIM. A low-dose regimen of RTX appears to be effective in maintaining remission after induction with standard dose. Key Points • The precise pathogenic mechanism of idiopathic inflammatory myopathies (IIM) remains elusive; however, a growing body of data support the autoimmune hypothesis. In this context, rituximab, a B cell-depleting agent, has emerged as a second-line therapeutic option in IIM. • Several studies have assessed It its effectiveness in refractory IIM patients. • Limited information exists on the use of Rituximab as maintenance therapy in patients who have achieved remission following induction therapy with Rituximab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RituximabMyositisRemission InductionHumansRetrospective StudiesMaleFemaleMiddle AgedAdultTreatment OutcomeAgedAntirheumatic AgentsGlucocorticoids

Stichwörter der Autor:innen

Inflammatory myopathiesInterstitial lung diseaseMaintenance treatmentRituximab

Substanzen

RituximabAntirheumatic AgentsGlucocorticoids

Autor:innen und Institutionen

  • Rheumatology Unit, Division of Rheumatology, Department of Medicine-DIMED, University of Padova, Via Giustiniani, 2, 35128, Padova, Italy.
  • Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy.
  • Academic Rheumatology Centre, Department of Clinical and Biological Sciences, University of Turin, AO Mauriziano di Torino, Turin, Italy.
  • Rheumatology Unit, Division of Rheumatology, Department of Medicine-DIMED, University of Padova, Via Giustiniani, 2, 35128, Padova, Italy. luca.iaccarino@unipd.it.

Förderung

  • Università degli Studi di Padova

Zitieren

APA

Gamba, A., Depascale, R., Zanatta, E., Ienna, L., Cruciani, C., Gatto, M., Zen, M., Doria, A., & Iaccarino, L. (2024). Effectiveness and safety of low dose Rituximab as remission-maintenance treatment for patients with refractory idiopathic inflammatory myopathies: results of a retrospective study from a monocentric cohort. Clinical Rheumatology. https://doi.org/10.1007/s10067-024-07079-z

Vancouver

Gamba A, Depascale R, Zanatta E, Ienna L, Cruciani C, Gatto M, et al. Effectiveness and safety of low dose Rituximab as remission-maintenance treatment for patients with refractory idiopathic inflammatory myopathies: results of a retrospective study from a monocentric cohort. Clinical Rheumatology. 2024. doi:10.1007/s10067-024-07079-z

BibTeX
@article{Gamba2024,
  author = {Gamba, Anna and Depascale, Roberto and Zanatta, Elisabetta and Ienna, Luana and Cruciani, Claudio and Gatto, Mariele and Zen, Margherita and Doria, Andrea and Iaccarino, Luca},
  title = {Effectiveness and safety of low dose Rituximab as remission-maintenance treatment for patients with refractory idiopathic inflammatory myopathies: results of a retrospective study from a monocentric cohort},
  journal = {Clinical Rheumatology},
  year = {2024},
  doi = {10.1007/s10067-024-07079-z}
}
Kostenlos starten →